Allergan-Inamed Deal OK’d By Federal Trade Commission; Closure Imminent
This article was originally published in The Gray Sheet
Executive Summary
Allergan's $3.2 bil. acquisition of aesthetics firm Inamed was set to close March 10, following Federal Trade Commission approval of the deal on March 8
You may also be interested in...
J&J Adds Aesthetics To Ethicon With $1.07 Billion Mentor Acquisition
Johnson & Johnson will take control of about half of the worldwide breast implant market and gain liposuction and body contour surgery products with its $1.07 billion acquisition of Mentor
J&J Adds Aesthetics To Ethicon With $1.07 Billion Mentor Acquisition
Johnson & Johnson will take control of about half of the worldwide breast implant market and gain liposuction and body contour surgery products with its $1.07 billion acquisition of Mentor
Allergan’s Inamed Purchase Delayed; Reloxin Will Go To Medicis
Allergan was forced to push back its $3.2 bil. purchase of Inamed after failing to obtain the requisite amount of stock from Inamed shareholders